Experiences of melt fi ll production of Fenretinide/Lym-X-Sorb™ hard gelatin capsules for Phase I clinical trial

Elliott, M.A. and Prasad, E. and Ford, S.J. and Halbert, G.W. (2010) Experiences of melt fi ll production of Fenretinide/Lym-X-Sorb™ hard gelatin capsules for Phase I clinical trial. In: UK-PharmSci 2010 – The Science of Medicines, 2010-09-01 - 2010-09-03.

Preview

Text. Filename: Elliot_etal_PharmSci_2010_Experiences_of_melt_fi_ll_production_of_Fenretinide_Lym_X_Sorb_hard_gelatin_capsules.pdf Download (218kB)| Preview

Abstract

Fenretinide is a pro-apoptotic, cytotoxic, synthetic Vitamin A analogue with application in the treatment of Ewing’s sarcoma. For pediatric study, a ‘cookie dough’ formulation had been developed, improving upon an existing corn oil formulation. We report on a simplified capsular formulation of Fenretinide with the novel solubility and bioavailability enhancing lipid matrix, Lym-X-Sorb™.

• Share and Export
  

  RDF+XMLBibTeXRIOXX2 XMLRDF+N-TriplesJSONDublin CoreAtomSimple MetadataReferMETSHTML CitationASCII CitationOpenURL ContextObjectEndNoteOpenURL ContextObject in SpanMODSMPEG-21 DIDLEP3 XMLData Cite XMLRIS (EndNote Online, Zotero, Ref manager, etc)RDF+N3Multiline CSV
• Item metadata

  Item type:	Conference or Workshop Item(Poster)
  ID code:	77983
  Dates:	Date Event 3 September 2010 Published
  Subjects:	Medicine > Therapeutics. Pharmacology
  Department:	Faculty of Science > Strathclyde Institute of Pharmacy and Biomedical Sciences Technology and Innovation Centre > Continuous Manufacturing and Crystallisation (CMAC)
  Depositing user:	Pure Administrator
  Date deposited:	01 Oct 2021 15:13
  Last modified:	09 Apr 2024 06:54
  URI:	https://strathprints.strath.ac.uk/id/eprint/77983